¿µÁø¸àʽºÅ©¸²(¿°»êºÎÅ׳ªÇÉ) (450g) MENTAX CREAM.[Butenafine HCl]
ÀϹÝÀǾàǰ | ±Þ¿© | ½Å¾à
¾Ë¸²:
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù.
Àü¹®/ÀϹÝ
ÀϹÝ
¹é»öÀÇ Å©¸²À¸·Î ¾à°£ ƯÀÌÇÑ ³¿»õ°¡ ÀÖ´Ù
Á¦Á¶È¸»ç
¿µÁø¾àǰ(ÁÖ)
ÆÇ¸Åȸ»ç
¿µÁø¾àǰ(ÁÖ)
Çã°¡Á¤º¸
Á¤»ó
(1994.01.17)
BIT ¾àÈ¿ºÐ·ù
Ç×Áø±ÕÁ¦ (Antifungal Agents)
º¹ÁöºÎºÐ·ù
265[±â»ý¼º ÇǺÎÁúȯ¿ëÁ¦ ]
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå
642400733 \85,374 ¿ø/450g/Åë(2021.09.01) (ÇöÀç¾à°¡) \111,600 ¿ø/450g/Åë(2020.07.01) (º¯°æÀü¾à°¡)
ATCÄÚµå
Butenafine / D01AE23
NDCÄÚµå
[Proprietary Name Search _ ƯÇãµî·Ï¸í,»óÇ¥¸íÀ¸·Î °Ë»ö]
[Active Ingredient Search _ ÁÖ¼ººÐÀ¸·Î °Ë»ö]
[NDC Number Search _ NDCÄÚµå·Î °Ë»ö]
¼ººÐ / ÇÔ·®
[½ÉÆò¿ø ÁÖ¼ººÐÄÚµå ±âÁØ ¼ººÐÇÔ·®Á¤º¸ Á¶È¸]
÷°¡Á¦
±Û¸®¼¼¸° ,
±Û¸®¼¼¸±½ºÅ׾Ʒ¹ÀÌÆ®SE ,
µð¿¡Åº¿Ã¾Æ¹Î ,
¹é»ö¹Ù¼¿¸° ,
º¥Á¶»ê³ªÆ®·ý ,
¼¼Åº¿Ã ,
½ºÅ׾Ƹ£»ê ,
Á¤Á¦¼ö ,
Æú¸®¿Á½Ã¿¡Æ¿·»¼¼Æ¿¿¡Å׸£ ,
ÇÁ·ÎÇÊ·»±Û¸®ÄÝÁö¹æ»ê¿¡½ºÅ׸£
À¯·áȸ¿ø °áÀç½Ã ¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸ ¸¦
ÀÌ¿ë ÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·Ï Àº Àü¹®È¸¿ø À¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
Çã°¡Á¤º¸
Ç׸ñ
³»¿ë
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇѱݾ×
642400733
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\85,374 ¿ø/450g/Åë(2021.09.01) (ÇöÀç¾à°¡)
\111,600 ¿ø/450g/Åë(2020.07.01)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁý ´Ù¿î·Îµå]
[¿ì¸®Áý°Ç°ÁÖÄ¡ÀÇ ¹Ù·Î°¡±â]
ºü¸¥Á¶È¸
Á¦Ç°¼º»ó
¹é»öÀÇ Å©¸²À¸·Î ¾à°£ ƯÀÌÇÑ ³¿»õ°¡ ÀÖ´Ù
[Á¦ÇüÁ¤º¸ È®ÀÎ]
Æ÷À塤À¯Åë´ÜÀ§
10g,20g,450g
Æ÷À塤ÄÚµå´ÜÀ§
¾àǰ±Ô°Ý
´ÜÀ§
´ëÇ¥ÄÚµå
Ç¥ÁØÄÚµå
ºñ°í
450±×·¥
1 °³
8806424007302
8806424007333
ÁÖ¼ººÐÄÚµå
120935CCM
[µ¿ÀÏÇÑ ÁÖ¼ººÐÄڵ带 °¡Áø ¿À¸®Áö³¯ ¶Ç´Â Á¦³×¸¯ ÀǾàǰ Á¶È¸]
´ëÇ¥ÄÚµå
8806424007302
º¸°ü¹æ¹ý
Â÷±¤,±â¹Ð¿ë±â, ½Ç¿Âº¸°ü
¾à¸®ÀÛ¿ë
[Á¶È¸]
È¿´ÉÈ¿°ú
[ÀûÀÀÁõ º° °Ë»ö]
´ÙÀ½ÀÇ ÇǺÎÁø±ÕÁõ
1) ¹é¼± : Á·ºÎ¹é¼±(¹ß¹é¼±Áõ,¹«Á»), °íºÎ¹é¼±(´ëÅðºÎ¹é¼±)(¿Ï¼±(»çŸ±¸´Ï¹é¼±(Áõ))), üºÎ¹é¼±
2) ¾î·ç·¯±â
¿ë¹ý¿ë·®
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
1ÀÏ 1ȸ ȯºÎ(ÁúȯºÎÀ§)¿¡ ¹Ù¸¥´Ù.
Ä¡·á±â°£ ÀÌÈÄ¿¡µµ ÀÓ»óÀûÀÎ Áõ»óÀÌ °³¼±µÇÁö ¾ÊÀ¸¸é Áø´ÜÀ» ´Ù½Ã ÇØ¾ß ÇÑ´Ù.
±Ý±â
ÀÌ ¾à ¼ººÐ¿¡ °ú¹ÎÁõÀÇ º´·ÂÀÌ Àִ ȯÀÚ
½ÅÁßÅõ¿©
¾Ë¸±¾Æ¹Î°è Ç×Áø±ÕÁ¦¿¡ ¹Î°¨ÇÑ È¯ÀÚ(±³Â÷¹ÝÀÀÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù)
ÀÌ»ó¹ÝÀÀ
ÇǺΠ: ¶§¶§·Î ±¹¼ÒÀڱذ¨, ¹ßÀû (ÃæÇ÷µÇ¾î ºÓ¾îÁü), È«¹Ý(ºÓÀº ¹ÝÁ¡), °¡·Á¿ò, Á¢ÃËÇǺο°, ¼öÆ÷(¹°Áý), µå¹°°Ô ¹Ì¶õ(Áþ¹«¸§), Àμ³(ºñ´Ã²®Áú), ±Õ¿(Æ´»õ,¿Ã¢)ÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
ÀϹÝÀû ÁÖÀÇ
1) ÀÌ ¾à »ç¿ëÀ¸·Î ÀÎÇØ ÀÚ±Ø ¶Ç´Â ¹Î°¨¼ºÀÌ ³ªÅ¸³ª¸é Ä¡·á¸¦ ÁßÁöÇϰí ÀûÀýÇÑ ¿ä¹ýÀ» ½Ç½ÃÇÑ´Ù.
2) ¼ö»êÈÄ®·ý¿ë¾×À¸·Î Á÷Á¢ÀûÀÎ Çö¹Ì°æÀû °Ë»ç ¶Ç´Â Àû´çÇÑ ¹èÁö¿¡ ¹è¾çÇÔÀ¸·Î½á Áúº´ÀÇ Áø´ÜÀ» È®ÀÎÇÒ ¼ö ÀÖ´Ù.
3) ÀÇ»çÀÇ Áö½Ã°¡ ¾ø´Â ÇÑ ¹ÐºÀºØ´ë¹ý ¶Ç´Â Æ÷Àå¹ýÀ» »ç¿ëÇÏÁö ¾Ê´Â´Ù.
4) ÀûÀÀÁõ ÀÌ¿ÜÀÇ Áúȯ¿¡ ÀÌ ¾àÀ» Åõ¿©ÇÏÁö ¾Ê´Â´Ù.
5) ÀÌ ¾à¿¡ ´ëÇÑ ¹ÝÀÀÀÌ ³ªÅ¸³ªÁö ¾ÊÀ¸¸é Áø±ÕÇÐÀûÀÎ °Ë»ç¸¦ ½Ç½ÃÇÏ¿© ´Ù¸¥ º´¿ø±Õ¿¡ ÀÇÇÑ °¨¿° ¿©ºÎ È®ÀÎ ÈÄ ´Ù¸¥ Ç×Áø±Õ¿ä¹ýÀ» ½ÃÇàÇÑ´Ù.
6) ÀÌ ¾àÀº ¾È½ÄÇâ»ê ³ªÆ®·ýÀ» Æ÷ÇÔÇϰí ÀÖÀ¸¸ç, ¾È½ÄÇâ»êÀº ÇǺÎ, ´«, Á¡¸·¿¡ °æ¹Ì(°¡º¿î,´ë¼ö·ÓÁö¾ÊÀº)ÇÑ ÀÚ±ØÀÌ µÉ ¼ö ÀÖ´Ù.
ÀӺο¡ ´ëÇÑ Åõ¿©
[ÀӺαݱ⠼ººÐ Á¶È¸]
ÀӽŠÁßÀÇ »ç¿ë¿¡ ´ëÇÑ ¾ÈÀü¼ºÀÌ È®¸³µÇ¾î ÀÖÁö ¾ÊÀ¸¹Ç·Î ÀӺΠ¶Ç´Â ÀÓ½ÅÇϰí ÀÖÀ» °¡´É¼ºÀÌ ÀÖ´Â ºÎÀο¡´Â Ä¡·á»óÀÇ À¯ÀͼºÀÌ À§Ç輺À» »óȸÇÑ´Ù°í ÆÇ´ÜµÇ´Â °æ¿ì¿¡¸¸ Åõ¿©ÇÑ´Ù.
¼öÀ¯ºÎ¿¡ ´ëÇÑ Åõ¿©
ÀÌ ¾àÀÇ ¸ðÀ¯·ÎÀÇ ÀÌÇà ¿©ºÎ¿¡ ´ëÇØ ¾Ë·ÁÁø ¹Ù ¾øÀ¸³ª ¸¹Àº ¾à¹°µéÀÌ ¸ðÀ¯·Î ÀÌÇàÇϹǷΠ¼öÀ¯ºÎ¿¡ ÀÌ ¾à Åõ¿©½Ã ÁÖÀÇÇÑ´Ù.
¼Ò¾Æ¿¡ ´ëÇÑ Åõ¿©
¼Ò¾Æ¿¡ ´ëÇÑ Åõ¿©
¹Ì¼÷¾Æ, ½Å»ý¾Æ ¹× 12¼¼ ÀÌÇÏÀÇ ¼Ò¾Æ¿¡ ´ëÇÑ ¾ÈÀü¼º ¹× À¯È¿¼ºÀÌ È®¸³µÇ¾î ÀÖÁö ¾Ê´Ù.
Àû¿ë»óÀÇ ÁÖÀÇ
1) ÀÌ ¾àÀº ¿Ü¿ëÀ¸·Î¸¸ Àû¿ëÇÑ´Ù.
2) ´«, ÄÚ, ÀÔ ¹× ´Ù¸¥ Á¡¸·¿¡ ´êÁö ¾Êµµ·Ï ÁÖÀÇÇÏ¿© Àû¿ëÇÑ´Ù.
3) ½ÉÇÑ ¹Ì¶õ(Áþ¹«¸§) ºÎÀ§¿¡´Â »ç¿ëÇÏÁö ¾Ê´Â´Ù.
4) Á·ºÎ¹é¼±(¹ß¹é¼±Áõ,¹«Á»), üºÎ¹é¼±, ¿Ï¼±(»çŸ±¸´Ï¹é¼±(Áõ)) ȯÀÚÀÇ È¯ºÎ(ÁúȯºÎÀ§) ¹× ±× ÁÖÀ§ÀÇ ÇǺθ¦ µ¤À» ¼ö ÀÖµµ·Ï ÀÌ ¾àÀ» ÃæºÐÈ÷ Àû¿ëÇÑ´Ù.
5) ÀÌ ¾àÀ» Àû¿ëÇϱâ Àü¿¡ ȯºÎ¸¦ ±ú²ýÀÌ ¾Ä°í ¿ÏÀüÈ÷ °ÇÁ¶½ÃŲ ÈÄ¿¡ Àû¿ëÇϸç Àû¿ëÈÄ¿¡´Â ¼ÕÀ» ¾Ä´Â´Ù.
º¸°ü ¹× Ãë±Þ»óÀÇ ÁÖÀÇ
¾î¸°ÀÌÀÇ ¼ÕÀÌ ´êÁö ¾Ê´Â °÷¿¡ º¸°üÇÑ´Ù.
Related FDA Approved Drug
±âÁØ ¼ººÐ:
BUTENAFINE HYDROCHLORIDE LOTRIMIN ULTRA (BUTENAFINE HYDROCHLORIDE)
MENTAX (BUTENAFINE HYDROCHLORIDE)
MENTAX-TC (BUTENAFINE HYDROCHLORIDE)
Á¤º¸¿ä¾à
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
ÄÚµå ¹× ºÐ·ùÁ¤º¸
Á¦Ç°Á¤º¸
º¹¾àÁ¤º¸
Ç׸ñ
³»¿ë
LACTmed ¹Ù·Î°¡±â
[¹Ù·Î°¡±â]
¾à¸®ÀÛ¿ë
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
Ãà¾àº¹¾àÁöµµ
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
º¹¾àÁöµµ
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
ÀӺο¡´ëÇÑÅõ¿©
*
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
 
FDA : Bµî±Þ
*
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
*
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
Pharmacokinetics
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
Á¦Çüº° º¹¾àÁöµµ
[Å©¸²]
º¸°ü»ó ÁÖÀÇ
Á¶Á¦½Ã ÁÖÀÇ
½É»çÁ¤º¸
ÇмúÁ¤º¸
Ç׸ñ
³»¿ë
DUR (ÀǾàǰ»ç¿ëÆò°¡)
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
Mechanism of Action
Butenafine¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Like allylamines, butenafine inhibits ergosterol biosynthesis by blocking squalene epoxidation. As ergosterol is an essential component of the fungal cell membrane, inhibition of its synthesis results in increased cellular permeability causing leakage of cellular contents.
Pharmacology
Butenafine¿¡ ´ëÇÑ Pharmacology Á¤º¸ Butenafine is an antifungal agent that acts by inhibiting squalene epoxidase, thus blocking the biosynthesis of ergosterol, an essential component of fungal cell membranes. It is mainly active against dermatophytes and has superior fungicidal activity against this group of fungi when compared to that of terbinafine, naftifine, tolnaftate, clotrimazole, and bifonazole. It is active also against Candida albicans and this activity is superior to that of terbinafine and naftifine. Butenafine also generates low MICs for Cryptococcus neoformans and Aspergillus spp. as well.
Half-life
Butenafine¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ Following topical application, a biphasic decline of plasma butenafine concentrations was observed with the half-lives estimated to be 35 hours initial and over 150 hours terminal.
Absorption
Butenafine¿¡ ´ëÇÑ Absorption Á¤º¸ The total amount absorbed through the skin into the systemic circulation has not been quantified.
Pharmacokinetics
Butenafine HClÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
Èí¼ö : ¿Ü¿ë : °ÅÀÇ Èí¼öµÇÁö ¾Ê´Â´Ù.
ºÐÆ÷ : ÇǺο¡ ºÐÆ÷ÇÑ´Ù.
´ë»ç : °£´ë»çµÈ´Ù.
¹Ý°¨±â : 35½Ã°£
Ç÷ÁßÃÖ°í³óµµ µµ´Þ½Ã°£ : ¿Ü¿ë : 6-15 ½Ã°£
¼Ò½Ç : ¿Ü¿ë : ¼Ò·®ÀÌ ½Å¹è¼³µÈ´Ù.
Biotransformation
Butenafine¿¡ ´ëÇÑ Biotransformation Á¤º¸ The primary metabolite in urine was formed through hydroxylation at the terminal t -butyl side-chain.
Toxicity
Butenafine¿¡ ´ëÇÑ Toxicity Á¤º¸ Not Available
Drug Interactions
Butenafine¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Not Available
CYP450 Drug Interaction
[CYP450 TableÁ÷Á¢Á¶È¸]
Drug Target
[Drug Target]
Description
Butenafine¿¡ ´ëÇÑ Description Á¤º¸ Butenafine hydrochloride is a synthetic benzylamine antifungal agent. Butenafine works by inhibiting the synthesis of ergosterol by inhibiting squalene epoxidase, an enzyme responsible for the creation of sterols needed in fungal cell membranes.
Drug Category
Butenafine¿¡ ´ëÇÑ Drug_Category Á¤º¸ Antifungal Agents
Smiles String Canonical
Butenafine¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CN(CC1=CC=C(C=C1)C(C)(C)C)CC1=CC=CC2=CC=CC=C12
Smiles String Isomeric
Butenafine¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CN(CC1=CC=C(C=C1)C(C)(C)C)CC1=CC=CC2=CC=CC=C12
InChI Identifier
Butenafine¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C23H27N/c1-23(2,3)21-14-12-18(13-15-21)16-24(4)17-20-10-7-9-19-8-5-6-11-22(19)20/h5-15H,16-17H2,1-4H3
Chemical IUPAC Name
Butenafine¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 1-(4-tert-butylphenyl)-N-methyl-N-(naphthalen-1-ylmethyl)methanamine
»ç¿ëÀÚÄÁÅÙÃ÷
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2021-09-23
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
¾Ë¸²
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù.
°æ°í
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡± ¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â ·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ